Merck Research from a Long-Term Business Owner's Perspective

Hunting ten-year five-baggers among great growth stocks — pressing the upside question: "Can it get much bigger?"

• QHow high is its market ceiling? Is it expanding an existing market, or creating an entirely new one?6/10

  A

  The ceiling is high enough, but Merck is mainly taking share from and expanding an already large existing market, rather than creating a new market from scratch. That is the first reason it does not fit Baillie Gifford's LTGG narrative of a fivefold return in ten years.

  Start with the size of the market itself. The report cites the IARC/WHO framework: global new cancer cases are expected to rise from about 20 million in 2022 to more than 35 million in 2050, an increase of about 77%. This long runway is real. The World Health Organization's February 2024 press release confirms that new cases in 2050 will exceed 35 million, about 77% higher than the 20 million in 2022. End demand for oncology treatment, cardiopulmonary therapies, vaccines, and animal health should rise for a long time with population aging and disease burden. There is little dispute on that point.

  But a high industry ceiling is not the same as this company creating a new market. Merck's core playbook is to use validated PD-1 therapies such as Keytruda to penetrate an already existing and highly competitive immuno-oncology market. According to the company's FY2025 earnings release, Keytruda/Keytruda Qlex generated full-year sales of $31.7 billion ($31.7 billion, up 7%), accounting for 49% of total company sales. It is the largest piece of this existing market, but the essence is deepening and broadening PD-1 indications one by one. Merck is the share leader in an existing market, not the creator of an unprecedented category. The report's 3/5 score for industry attractiveness under market ceiling reaches the same judgment: demand is strong and the profit pool is large, but it is redistributed by patent cliffs and regulation.

  The parts with some new-market-creation flavor are its newer growth pillars, not the core business. According to the report, management said in its first-quarter 2026 prepared remarks that the company was in the initial launch phase of more than 20 new growth drivers, which together could represent more than $70 billion of commercial opportunity by the mid-2030s. Winrevair for pulmonary arterial hypertension, Capvaxive for adult pneumococcal vaccination, and Ohtuvayre for COPD, which came through the $10 billion acquisition of Verona Pharma, are indeed expanding into new therapeutic areas. But these look more like taking new share in adjacent large disease categories. Their scale is still far smaller than Keytruda's, and $70 billion is an opportunity ceiling, not banked revenue.

  The practical conclusion: Merck's industry ceiling is high enough to keep it from hitting a wall, but its growth model is to take more share inside a huge existing market and expand into adjacent diseases. It is not the Baillie Gifford-preferred case of creating a wholly new market and reshaping an industry. For this question, Merck is a strong player in a large existing market, not the maker of a new one.

  Jun 10, 2026
• QCan its revenue at least double over the next five years? Will growth be driven mainly by volume, price, or new businesses?3/10

  A

  Almost certainly not. A doubling of Merck's revenue over the next five years, from about $65 billion to $130 billion, is unrealistic. On the contrary, the 2028-2029 Keytruda patent cliff means the middle of this five-year period will probably be about absorbing a revenue bleed before any thought of doubling.

  Start with the base and recent growth. According to the company's FY2025 earnings release, full-year sales were $65.011 billion, up only about 1% year on year ($65,011 million vs $64,168 million in 2024). The report's financial table also shows revenue rising from $48.704 billion in 2021 to $65.011 billion in 2025, a cumulative gain of about 33% over four years and an annualized rate of about 7.5%. That is solid growth for a large pharmaceutical company, but it is less than half of the roughly 15% compound annual growth needed to double in five years. There is almost no precedent for a mature drug company with $65 billion of revenue and its largest product approaching a cliff to sustain 15% annualized growth.

  The more important issue is the structural headwind in the middle of the period. The report states clearly that the company warned in its 10-K that Keytruda will face material biosimilar impact in 2028 to 2029, while Keytruda alone accounted for 49% of 2025 total sales. That means nearly half of the revenue base starts coming under pressure from 2028. Third-party research also supports the scale of this cliff. A market report cited by GlobeNewswire expects the Keytruda market to decline by 2030 as patents expire and biosimilar competition arrives. In other words, Merck's issue over these five years is not how to double, but whether new products can fill the hole left by Keytruda erosion and prevent a sharp decline in total revenue.

  So what drives growth: volume, price, or new business? Each has constraints. Price: room for price increases is narrowing under IRA price negotiations, CDC dose recommendations, international pricing pressure, and reimbursement access limits. The report judges pricing power as present during the patent period, but constrained by insurers, governments, and international pricing. Volume: during the patent period, Keytruda can still grow through new indications and the subcutaneous formulation Keytruda Qlex, which received FDA approval on September 19, 2025. After 2028, however, both volume and price are likely to fall. New businesses: this is the only true source of incremental growth. It includes Winrevair ($1.4 billion of sales in 2025), Capvaxive ($759 million), Ohtuvayre, and management's framing of more than 20 new growth drivers with more than $70 billion of combined opportunity by the mid-2030s. But this is an opportunity ceiling across a decade and has not yet been realized. Even partial success would look more like filling the hole plus modest growth than doubling the overall business.

  The practical conclusion: Merck doubling revenue over the next five years is unrealistic, and market consensus does not expect it. The real contest over these five years is whether the new-product portfolio can offset the decline during the Keytruda cliff, stabilize revenue first, and then allow a gradual recovery. For a framework looking for fivefold growth stocks over ten years, Merck gives a clear negative answer on this question.

  Jun 10, 2026
• QAfter five years, what will take over as the next growth engine? Does this second curve exist today?5/10

  A

  The second curve has already been born but has not yet matured. It consists of a basket of new products (Winrevair, Capvaxive, Ohtuvayre, Welireg) and a large amount of acquired pipeline. The direction is real, but the current scale is far too small to take over from Keytruda on its own. Whether it can fill the post-2028 hole remains the company's biggest uncertainty.

  First, confirm that the second curve really exists and is not a slide deck. Products already launched and beginning to scale include Winrevair (pulmonary arterial hypertension, $1.4 billion of sales in 2025), Capvaxive (adult pneumococcal vaccine, $759 million of sales in 2025), Welireg (VHL-associated tumors), and Ohtuvayre, the first-in-class maintenance therapy for COPD obtained through the $10 billion acquisition of Verona Pharma. The report describes these as real but not yet fully validated succession paths for the post-Keytruda era. That characterization is accurate: they are real medicines with real end demand, but each product's current annual sales are still a fraction of Keytruda's $31.7 billion.

  Management's framing of the total second curve, as cited from the report's first-quarter 2026 prepared remarks, is that the company is in the initial launch phase of more than 20 new growth drivers that together could represent more than $70 billion of commercial opportunity by the mid-2030s. If even half of that number is realized, it could theoretically cover Keytruda's potential loss. But between opportunity and revenue stand Phase 3 readouts, approvals, reimbursement access, and commercial ramp-up. Any one of those gates can eliminate a candidate.

  One defining feature of the second curve is that it is increasingly bought rather than grown. The report says Merck completed the $9.2 billion acquisition of Cidara in the first quarter of 2026, creating about $9.0 billion of one-time acquired R&D asset charges, and signed an agreement to acquire Terns in the same period for a total transaction value of about $6.7 billion. Both transactions are supported by primary or direct sources: CNBC reported that Terns was acquired for about $6.7 billion ($53/share, about $6.7 billion, targeting chronic myeloid leukemia assets), on top of the earlier $10 billion Verona deal. In other words, a meaningful share of Merck's post-Keytruda growth engine is pipeline purchased with the balance sheet, while the share contributed by its own labs is declining. This shifts the judgment from whether the company's R&D can succeed to whether the company can earn back the money it spends on M&A. The report therefore rates capital allocation as uncertain.

  Measured against Baillie Gifford's ideal second curve, a new main trunk that is already clearly visible today, driven by internal capability, and capable of growing into an independent giant, Merck only partially satisfies the test. The curve exists and points in the right direction, but it is spread across a dozen-plus small and mid-sized products. None appears capable of supporting half the company the way Keytruda does, and the curve is highly dependent on acquisitions and future clinical execution. Practical conclusion: the second curve is visible and tangible today, but whether it can become large enough during the 2028-2031 window to take over is the most uncertain part of this investment and the metric that most needs continued tracking. The report also lists it as the top monitoring item.

  Jun 10, 2026
• QWhat is its core competitive advantage? Will this moat widen or narrow over the next three to five years?5/10

  A

  The moat is real but comes with a timer. It consists of patent exclusivity, regulatory barriers, a vast clinical-data base, global commercialization scale, and oncology academic standing. Over the next three to five years, however, the main wall of this moat, the Keytruda patent estate, is approaching expiry. The overall direction is narrowing rather than widening. The company is rushing to build a second line of defense, but it is not finished.

  Start with the source of the moat. The report identifies Merck's strongest barriers as patents, regulatory barriers, accumulated clinical data, global commercialization scale, and oncology academic standing, not consumer-style brand network effects. The company's own 10-K states that patent protection is materially important to product marketing in the aggregate and gives key product expiry dates: Keytruda core U.S. patent milestones in 2028/2029, Europe in 2031, China in 2028; Gardasil U.S. in 2028; Bravecto in 2027; Prevymis in 2029. This is a real moat. During the patent period, Keytruda has pricing power and a near-exclusive market position. That is the foundation of its $31.7 billion of annual sales and its 49% share of company revenue.

  But direction matters. The report gives moat strength a 3/5 and states directly: if one looked only at operating performance before 2025, the score could even be higher; once the 2028-2029 biosimilar pressure on Keytruda is included, one has to admit that this moat is not widening and instead looks like a main wall approaching expiry while the company is rushing to build a second line of defense. This judgment is supported by primary sources: the company's 10-K has already warned that Keytruda will face material biosimilar impact in 2028-2029, and multiple biosimilar manufacturers, including Samsung Bioepis and Amgen, are waiting to launch after U.S. patents expire in 2028. The nature of a patent moat is that it has a time limit. On the expiry date, molecule substitution can be very brutal, the word used in the report.

  How far along is the second line of defense? Merck's hedging actions are real: the subcutaneous formulation Keytruda Qlex (approved by the FDA on September 19, 2025, reducing administration from 30 minutes intravenously to 1-2 minutes subcutaneously) may extend the lifecycle through convenience and new formulation patents. Add the ADC portfolio, Winrevair, Capvaxive, Welireg, Ohtuvayre, and external partnerships. But the report honestly adds that these have not all been validated as a sufficiently thick new moat. Item by item, scale advantages are strong, channel advantages are strong, and patent/regulatory barriers are very strong but time-limited. Network effects are weak, and cost advantage is limited; those were never Merck's strong suits.

  The practical conclusion: this is a high-quality moat being eroded by the clock. Over the next three to five years (2026-2030), as Keytruda enters its late patent period, the overall moat is narrowing. Whether it can widen again after narrowing depends on whether the second line of defense, new products plus acquired pipeline, can be validated in the same window. Against Baillie Gifford's standard that a moat should be widening, Merck today is closer to a narrowing moat with uncertain repair. That is also one of the core reasons the report assigns a final rating of Watch rather than Buy.

  Jun 10, 2026
• QIf the core business is disrupted, does it have the DNA to reinvent itself? How does it handle mistakes and bad news?5/10

  A

  It has some ability to reinvent itself, but the model leans more toward buying reinvention with money than evolving through organizational DNA. Merck's handling of bad news is candid disclosure and early positioning, which is a positive. But its reinvention depends heavily on avoiding major capital-allocation mistakes, and that is exactly where the report is least comfortable.

  Start with the implicit premise of reinvention DNA. For a pharmaceutical company, the core business, usually a blockbuster molecule, is almost destined to be disrupted, not by competitors alone, but by the patent-expiry time bomb. For Merck, the real question is not whether disruption will come, but whether each cash cow can be replaced or bought when it expires. Historically, Merck has gone through multiple patent transitions, including earlier products such as Singulair and Zetia, and eventually climbed back to the top with Keytruda. That shows organizational ability to change engines. The report also acknowledges this, rating culture and operating capability as above average, with both internal R&D and the ability to expand through partnerships/M&A.

  Its attitude toward bad news is an underappreciated strength. Merck does not avoid exposing its own risk zones: in its 10-K it directly states that Keytruda will face material biosimilar impact in 2028-2029, that sales typically decline significantly and rapidly once patents expire, and that Bridion and Januvia/Janumet will lose U.S. exclusivity in 2026. This is consistent with the company's FY2025 earnings release acknowledging a 39% full-year decline in Gardasil (sales of $5.2 billion). The report specifically notes that from February 2025 the company proactively paused Gardasil shipments to China and directly told the market that related sales were not expected to recover meaningfully in 2026. This culture of putting bad news on the table without dressing it up is a positive signal for the Baillie Gifford question of how it treats mistakes and bad news.

  But the way Merck reinvents itself deserves caution: it is increasingly bought. The report says Merck completed the $9.2 billion acquisition of Cidara in the first quarter of 2026, creating about $9.0 billion of one-time acquired R&D asset charges, signed the acquisition of Terns (about $6.7 billion) in the same period, and added the $10 billion Verona Pharma deal. Three large BD transactions in a short period show that Merck is actively trying to change rather than waiting for the cliff. That is an active reinvention posture. But it also puts the success or failure of reinvention on whether acquired pipelines deliver and whether the company avoids systematic overpayment. The report therefore rates capital allocation as uncertain and notes that whether ROIC can be maintained increasingly depends on whether externally purchased pipelines deliver. In other words, within its reinvention DNA, financial capacity is stronger than originality.

  The practical conclusion: Merck has a historical record of changing engines and a healthy culture of candidly facing bad news. Both are real positives. But its current reinvention path depends heavily on a string of large acquisitions succeeding, rather than purely on internal R&D compounding. That shifts the uncertainty of reinvention from scientific risk to capital-allocation risk. Whether investors can be comfortable depends on whether they trust management to maintain price discipline in acquisitions under the pressure of a patent cliff. The report lists this as one of the key assumptions.

  Jun 10, 2026
• QDoes management, especially the founder, have a long-term view and deep alignment with the company? Is it willing to sacrifice current profit for five to ten years from now?4/10

  A

  Management has a clear long-term view and is institutionally well aligned with shareholders. But this is a professional-manager team under a strong governance framework, with no founder-style deep ownership. Its willingness to sacrifice current profit for five to ten years from now shows up mainly through large M&A spending, not through the kind of founder long-termism backed by personal net worth.

  First, be clear about the founder alignment that Baillie Gifford values most: Merck has no founder. It is a mature pharmaceutical company with more than a century of history, run by professional managers. The report admits in the valuation and limitations section that detailed current share-ownership multiples for individual executives in the 2026 proxy statement were not forced into the report. In other words, even the exact executive ownership multiples could not be precisely obtained from accessible sources. That itself suggests management's personal economic alignment with the company is far weaker than that of a founder-controlled growth company with heavy founder ownership. This is a structural weakness for Merck under the Baillie Gifford framework: it lacks the alignment where a founder is willing to bet personal wealth on the company ten years out and sacrifice the present for that future.

  But the institutional alignment is solid. The report cites the 2025 proxy statement: more than 11 of the 12 director nominees are independent; all four standing committees consist entirely of independent directors; directors are elected annually; majority voting applies; executives and directors are prohibited from hedging, pledging, or short-selling company stock; directors and executives must hold meaningful amounts of company stock; proxy access exists; and there is no poison pill. On compensation, 2024 say-on-pay support was about 94%, incentive compensation is tied to long-term EPS and relative total shareholder return, and executives are required to retain a substantial portion of after-tax net share proceeds until ownership multiples are met. On that basis, the report rates management trustworthiness as a pass. This governance framework is indeed above average among large pharmaceutical companies.

  On whether Merck is willing to sacrifice current profit for five to ten years from now, the answer is yes, and it is doing so, but through spending rather than price concessions. The clearest evidence is its aggressive BD ahead of the patent cliff: the $9.2 billion acquisition of Cidara in the first quarter of 2026 created about $9.0 billion of one-time acquired R&D asset charges, directly pushing Q1 GAAP into a net loss. The report records Q1 GAAP net loss of $4.240 billion while operating cash flow was still $3.918 billion. Add Terns at about $6.7 billion and Verona at about $10 billion. Management knows these deals will depress short-term accounting profit, but still insists on betting early for growth in the 2030s. That is exactly the behavior of sacrificing current profit for the long term. At the same time, the company returned $13.3 billion to shareholders in 2025 ($8.2 billion of dividends, $5.1 billion of buybacks) and authorized up to $10 billion of additional buybacks, showing a balance between investing for the future and rewarding the present.

  The practical conclusion: this is a well-governed, long-term-minded, institutionally aligned professional management team, and it is putting real money behind the post-Keytruda era. But it lacks the incentive purity Baillie Gifford prefers: a founder with deep ownership tying personal destiny to the company ten years from now. Its sacrifice for the long term comes through large acquisitions, so the trust question lands on whether the money is being spent well. The report therefore separately keeps capital allocation at uncertain, reminding investors that credible governance is not the same as excellent capital allocation.

  Jun 10, 2026
• QIf it disappeared tomorrow, how much would customers miss it? Is its growth sustainable and not dependent on harming society or regulation?6/10

  A

  If Merck disappeared tomorrow, global oncology and public-health systems would miss it badly. Its indispensability is extremely high, with products that genuinely save lives, and its growth model is broadly sustainable and not built on harming society. But indispensability has two qualifiers: it is tied to molecules rather than the brand, so substitutes arrive once patents expire; and pricing and access issues keep it under the regulatory spotlight.

  Start with whether it would be missed. The answer is strongly yes. Keytruda is one of the world's best-selling prescription drugs and a backbone first-line/adjuvant therapy for non-small-cell lung cancer, melanoma, and dozens of other cancers. In 2025 it generated $31.7 billion of sales and accounted for 49% of the company. Gardasil is a key vaccine for preventing HPV-related cancers. Animal health supports the food supply chain and pet health. These are products whose disappearance would truly leave some patients without treatment. Indispensability here sits in the highest tier across industries. The report's checklist also marks long-term stable demand and pricing power as passing, grounded in this rigid, life-saving end demand.

  But this indispensability is tied to the molecule, not to the Merck name. That is the fundamental difference between pharmaceuticals and consumer/platform businesses. If Coca-Cola disappeared, others could not replicate the formula and brand; but after Keytruda's core U.S. patents expire in 2028, biosimilar manufacturers, including Samsung Bioepis and Amgen, can quickly launch equivalent pembrolizumab. Patients can still receive the medicine, just no longer from Merck. The report's judgment is sharp: switching costs are medium, but once the patent expires, molecule substitution can be very brutal. So it is true that customers cannot do without this type of treatment; it is also true that dependence on Merck as a company has a patent-clock expiry date.

  Next consider the dual premise of whether growth is sustainable and does not harm society or regulation. On the positive side, Merck's business fundamentally creates social value: extending cancer patients' lives, preventing infectious disease, and protecting animals and food safety. That is entirely different from business models built on addiction, regulatory arbitrage, or user harm, so the social sustainability case is defensible. But two ongoing regulatory/social frictions have to be named honestly. The first is pricing and access: Keytruda's high price has long drawn criticism, and the report notes that growth is constrained by IRA price negotiations, CDC dose recommendations, and international pricing pressure, with pricing flexibility narrowing. The second is patent evergreening controversy: Merck uses tools such as the subcutaneous formulation Keytruda Qlex (approved by the FDA in September 2025) to extend the lifecycle. This is commercially rational, but it also keeps the company under public and regulatory scrutiny around drug access. In other words, its growth does not rely on harming society, but it does walk the long-term regulatory tightrope between high drug prices and public access.

  The practical conclusion: Merck's products are indispensable and its growth model has social legitimacy, so it essentially passes this question. But it falls short of a Baillie Gifford full score for two reasons: indispensability is tied to expiring molecules rather than perpetual brands/networks, and high drug prices leave it persistently exposed to regulatory and pricing pressure. Those two points make the degree to which customers would miss it real but time-limited, and the sustainability real but subject to regulatory cycles.

  Jun 10, 2026
• QWhat are the unit economics of this business (gross margin, incremental returns)? Do they improve or deteriorate with scale? Where does the money it earns go?7/10

  A

  The unit economics are excellent: high gross margin (about 78%), high free-cash-flow conversion, and strong returns on capital. Scale allows fixed R&D and commercialization costs to be spread over a larger base, making this broadly a business that gets better as it gets bigger. The money earned mainly goes to three places: shareholder returns, capacity expansion, and increasingly large external acquisitions. The last item is the key variable pulling a high-quality cash cow toward execution risk.

  Start with the gross-margin and unit-economics foundation: very strong. Patented drugs and vaccines are classic high-gross-margin businesses. R&D and approval require huge upfront fixed costs, but once a product launches, the marginal cost of each additional unit is low. Under the company's financial reporting, Merck's GAAP gross margin for the first nine months of 2025 was about 77.7%, higher than 76.6% in the same period of 2024. The report also admits that the exact 2025 GAAP gross-margin figure was not forced into the report, but a nearly 78% gross margin is top-tier across industries and directly reflects how a patented blockbuster like Keytruda can make incremental sales close to pure profit.

  Next, incremental returns and whether scale improves or worsens the business: it improves it. The report states that scale is one of Merck's strongest moats: the company can simultaneously fund global clinical trials, registration, manufacturing, sales, and BD, and its large base helps absorb fixed costs. Financially, net margin reached 28.1% in 2025 (net income of $18.254 billion / revenue of $65.011 billion), the highest in five years. The report's checklist also marks return on capital as passing, saying recent ROE/ROIC has been strong, while warning about buybacks and accounting distortions. This is a business whose unit economics improve with scale, provided new molecules continue to launch and fill the global fixed-cost infrastructure.

  Where the money goes is the most informative part of this question, in three buckets:

  First, shareholder returns: substantial and real. The report says Merck returned $13.3 billion to shareholders in 2025 ($8.2 billion of dividends and $5.1 billion of buybacks) and authorized up to $10 billion of additional buybacks. Average diluted shares fell from 2.541 billion in 2024 to 2.507 billion in 2025.

  Second, capacity expansion and maintenance capital expenditure: 2025 capital expenditure was $4.112 billion, and the company has clearly planned about $20 billion of capital projects for 2025-2029, more than $12 billion of which is in the U.S. On this basis, the report calculates owner earnings (operating cash flow minus capital expenditure) at about $12.4-13.4 billion.

  Third, and most important, external M&A is consuming more and more cash. The report records upfront payments related to collaborations/licensing/acquisitions rising from $1.1 billion in 2024 to $3.0 billion in 2025. In 2026, large deals accelerated: according to the report, the Cidara acquisition was about $9.2 billion and created about $9.0 billion of one-time IPR&D charges; in the same period Merck signed Terns at about $6.7 billion ($53/share); and it had already completed Verona at about $10 billion. This shows cash use shifting from natural compounding plus shareholder returns toward buying pipeline for the post-Keytruda era.

  The practical conclusion: Merck's unit economics are one of the few clearly excellent items under the Baillie Gifford framework. High gross margin, high cash conversion, and positive scale feedback make it undeniably strong on this question. But where the money goes issues a warning: excellent unit economics are being put increasingly into large, unvalidated external acquisitions. Whether future ROIC holds depends on whether these purchased assets earn back the invested capital. That is also why the report uniquely keeps capital allocation at uncertain. The business itself has first-rate earning power, but the reinvestment return on those first-rate cash flows is entering a phase that needs close scrutiny.

  Jun 10, 2026
• QWhat conditions must all hold for it to rise fivefold in ten years? Are those conditions realistic? What expectations are embedded in today's share price?2/10

  A

  For MRK to rise fivefold in ten years, an almost impossible set of extreme conditions would have to hold at the same time. That conflicts with the nature of the business: a mature large pharmaceutical company facing a patent cliff in its main product. Today's share price of about $120 and market value of about $295 billion does not embed a fivefold expectation. It embeds the market's belief that the company can pass smoothly through the Keytruda cliff and sustain mid-single-digit returns. The valuation is not cheap, and it leaves no margin of safety for a fivefold outcome.

  First, quantify what fivefold would require. As of early June 2026, MRK was around $120, with a market value of about $295.4 billion, slightly below the report's May 22 snapshot of $122.41/about $302.3 billion. A fivefold increase over ten years would imply a market value of about $1.5 trillion and a compound annual return of about 17.5%. For a mature drug company with $65 billion of revenue and only about 1% growth in 2025, achieving 17.5% annualized shareholder returns would require at least the following conditions to hold simultaneously:

  First, Keytruda's erosion after the 2028-2029 patent cliff would have to be far slower than the company's own cautious expectations, and the subcutaneous formulation Keytruda Qlex (approved in September 2025) would have to keep biosimilars outside the gate for years. But the 10-K has already warned of material impact, and biosimilar manufacturers are already waiting for 2028 expiry. Slow erosion is a hope, not the base case.

  Second, management's more than 20 new growth drivers and more than $70 billion of combined opportunity by the mid-2030s would have to be realized in large proportion, rather than partially falling away. The acquired Cidara, Terns, and Verona pipelines would all have to commercialize successfully and earn returns above the cost of capital.

  Third, regulatory and demand headwinds such as IRA price negotiations, international pricing, and Gardasil pressure in China would have to avoid worsening further.

  Fourth, the valuation multiple would have to expand from today's level rather than contract as growth slows.

  Any one of these four conditions is difficult. The probability that all four hold together is very low. The report's three-scenario DCF confirms the same point: even in the optimistic case, where Keytruda formulation extension slows erosion, new growth drivers realize strongly, and external BD generates good returns, intrinsic value is only $125-145 per share. That is an order of magnitude away from fivefold to $600. In other words, even the report's own most optimistic assumptions cannot fit a fivefold return in ten years.

  What does today's price imply? The answer is a smooth transition, not explosive growth. The report estimates that based on conservative 2025 free cash flow of about $12.36 billion and the market value at the time, owner earnings yield was about 4.1%-4.4% and P/FCF about 24.5x. Using today's market value of about $295.4 billion, owner earnings yield is about 4.2% and P/FCF about 23.9x, essentially unchanged. Compared with the 10-year U.S. Treasury yield of about 4.5%, this offers almost no risk compensation. It shows that the market has already priced in a meaningful amount of post-patent-cliff repair success. Buying today is not buying a cheap asset the market hates while waiting for fivefold re-rating; it is buying a quality asset where the market already assumes a smooth handoff and assigns a reasonably expensive price. The report's expected annualized return ranges of conservative 3-5%, neutral 6-8%, and optimistic 9-11% reflect that embedded expectation.

  The practical conclusion: a fivefold return in ten years is unrealistic for MRK. The required combination of conditions is detached from the nature of the business, and even the report's most optimistic scenario cannot accommodate it. Today's share price does not embed fivefold expectations; it embeds a smooth passage through the cliff plus mid-single-digit returns. The valuation is therefore not cheap, sitting close to reasonable-to-optimistic territory, and it gives no discount for upside surprise. For a Baillie Gifford framework looking for fivefold returns in ten years, this is a clear negative. For a stability-oriented value investor, its appeal depends on whether the price can fall back to the report's ideal buying range of $85-100.

  Jun 10, 2026
• QWhy has the market not realized all this yet? Is it because investors do not understand, look down on it, or cannot see far enough? What will become the narrative inflection point?3/10

  A

  For MRK, this question needs to be honestly reversed: the market actually understands it quite well, and there is no obvious mispricing or neglect. The Keytruda patent cliff, new-pipeline handoff, and M&A risks are all public information and have been substantially priced in. This is not a stock waiting to be re-rated after being underestimated. It is a reasonably, perhaps slightly expensively, priced stock with highly symmetric bull and bear expectations. The real narrative inflection point is not the market suddenly understanding; it is the actual data from the 2028-2031 Keytruda cliff period proving or disproving today's smooth-transition assumption.

  Start by breaking the premise: this Baillie Gifford question assumes that the market has mispriced a great growth stock because investors do not understand it, look down on it, or cannot see far enough. MRK does not fit that premise. The report repeatedly emphasizes the core judgment: good company, average price, and insufficient margin of safety. That means the market has not underestimated it; it has assigned a fair-to-somewhat-expensive price. The evidence is valuation: at today's roughly $120 share price and about $295.4 billion market value, owner earnings yield is about 4.2% and P/FCF about 24x, with almost no risk compensation versus the 10-year U.S. Treasury yield of about 4.5%. A stock that is despised and mispriced would trade meaningfully below peers and the risk-free rate. MRK is the opposite.

  Where is the disagreement on MRK? It is not about whether the market understands; it is about an unknowable future after 2028. The report lays out relative valuation clearly: public-market data show MRK trading materially above Bristol Myers and AbbVie (the report's figures: BMY EV/EBITDA about 8.1x, ABBV about 10.6x, MRK about 12.4x), yet without the broadly accepted high-growth certainty of Eli Lilly (EV/EBITDA about 26x). In other words, the market's pricing of MRK precisely reflects its position: more expensive than peers that have already been through cliffs, cheaper than LLY with a clear growth engine. That is pricing that understands the situation, not an overlooked mispricing.

  If one must identify where the market may not see far enough, it is two-sided and symmetric. Bulls may underestimate the ability of subcutaneous Keytruda Qlex (approved in September 2025) to extend the lifecycle, and the upside from realizing more than 20 new growth drivers. More cautious investors may underestimate the speed of biosimilar erosion and the risk of acquisition returns. The report's strongest counterargument is that MRK may look superficially cheap while actually prepaying for the post-2028 profit gap. But that too is only a possibility, not a proven mispricing. Both sides are betting on the same unknown, which is exactly the signature of fair pricing and symmetric expectations.

  What will the narrative inflection point be? Not collective market enlightenment, but real data arriving. The report lists concrete signals that could trigger reassessment, and the most important are the likely inflection points: ① the actual quarterly erosion curve for Keytruda after 2028-2029 patent expiry, slower than expected creating upside and faster than expected creating downside; ② whether Keytruda Qlex formulation extension materially slows erosion; ③ the ramp speed of new products such as Winrevair, Capvaxive, and Ohtuvayre, and whether acquired Cidara, Terns, and Verona pipelines deliver; ④ whether Gardasil demand in China recovers. Directional evidence above expectations in any of these areas could become the trigger for revaluation. But before 2028 actually arrives, these remain assumptions, and the market can only price probabilities.

  The practical conclusion: MRK is not a hidden opportunity the market has not realized. It is a mature, high-quality stock the market fully understands and has priced fairly, perhaps slightly expensively. There is no obvious positive perception gap to arbitrage. That itself is the answer. The real inflection point is time and data: actual performance during the 2028-2031 Keytruda cliff will determine whether today's roughly $120 price was a fair price for mediocre returns or an excessive price for hidden downside. For the Baillie Gifford framework, this question does not give a market-is-wrong, get-on-board signal. For value investors, it means waiting patiently for a lower price, the report's $85-100 range, is more sensible than betting on a market epiphany.

  Jun 10, 2026